Prequalification of the MVA-BN vaccine by the World Health Organization (WHO) has proven to be yet another milestone in the global struggle against monkeypox.
Made by Bavarian Nordic A/S, the MVA-BN vaccine is the initial monkeypox vaccine ever endorsed, which will be accessible to people in the remote areas.
It is administered in two doses periodically but currently, the vaccine has demonstrated effectiveness in more than 80% of the cases of monkeypox, which a mere single dose currently protects around 76% of the people.
This targets adults, 18 and older, who are mainly those at high risk of transition especially the ones in healthcare and people with several sexual partners.
We need to stop the monkeypox outbreaks which currently have impacted over 120 countries with a lot of people either getting sick or dying.
WHO calls for amicable sharing of the vaccines in addition to the public health measures to get the monkeypox pandemic under procuration, internationally.